Cyclacel's David Glover to present at New York of Sciences Symposium
 

Pharmacologic Regulation of DNA Damage Checkpoints to Treat Cancer

BERKELEY HEIGHTS, NJ, March 4, 2008 – Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced today that its chief scientist, Professor David Glover will participate in a Symposium on "Pharmacologic Regulation of DNA Damage Checkpoints to Treat Cancer". The event will take place on Thursday, March 13, 2008 from 1:00 pm to 5:30 pm Eastern time at The New York Academy of Sciences (NYAS), located at 7 World Trade Center, 250 Greenwich Street, New York, NY.

Professor Glover, who joined Cyclacel’s management team in 1999, discovered and named the Aurora, Polo and other mitotic kinases, enzymes that play key roles in the regulation of cell division. He is the Arthur Balfour Professor of Genetics and chair of the Department of Genetics at the University of Cambridge in the United Kingdom and director of the Cancer Research UK Cell Cycle Genetics Research Group. He has authored over 200 publications and patents.

Professor Glover’s presentation at the NYAS will describe research into novel nucleoside analogs that lead to robust checkpoint arrest at the G2/M phase of the cell cycle. Professor Glover’s lecture will review new breakthroughs in this area of research that may lead to the development and commercialization of next generation nucleoside analogs. Nucleoside analogs such as cytarabine, 5-fluorouracil and gemcitabine have become an important part of the current cancer treatment armamentarium, but are limited by side effects and the development of resistance. An unmet medical need exists for the development of novel nucleoside analogs that are effective in a broader range of cancers with improved safety profiles.

The conference is open to the public.

For more information, please visit, www.nyas.org/events .

- ENDS -

About The New York Academy of Sciences – www.nyas.org 

Founded in 1817, the New York Academy of Sciences is an independent, nonprofit organization with 26,000 members in 140 countries. The Society's mission is to advance scientific knowledge, positively impact the major global challenges of society with solutions that are science-based, and increase the number of scientifically informed individuals in society at large.

About Cyclacel Pharmaceuticals, Inc – www.cyclacel.com 

Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three Cyclacel drugs are in clinical development. Sapacitabine (CYC682), an orally-available cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly and cutaneous T-cell lymphoma (CTCL). Seliciclib (CYC202), an orally-available CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. CYC116, an orally-available, Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. Several additional programs are at an earlier stage. Cyclacel’s ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair™ Cream for radiation dermatitis, Numoisyn™ Liquid and Numoisyn™ Lozenges for xerostomia. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in oncology, hematology and other therapeutic areas based on a portfolio of commercial products and a development pipeline of novel drug candidates.

Note: The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. Numoisyn™ and Xclair™ are trademarks of Sinclair Pharma plc.

Risk Factors

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2006, as supplemented by the interim quarterly reports, filed with the SEC.


Contacts for Cyclacel:

College Hill
Sue Charles / Justine Lamond / Claire Mosley
Ph : +44 (0)20 7866 7857
cyclacel@collegehill.com